These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 2681472)

  • 1. [Immunohistochemical study on oncogene product ras p 21 in thyroid carcinoma].
    Mochizuki Y; Nakayama I; Noguchi S
    Nihon Gan Chiryo Gakkai Shi; 1989 Aug; 24(8):1539-44. PubMed ID: 2681472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of ras oncogene product P21 in thyroid tumors: an immunohistochemical study].
    Gui K
    Zhonghua Yi Xue Za Zhi; 1990 Mar; 70(3):140-2, 12. PubMed ID: 2163739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ras p21 immunostaining in early stage squamous cervical carcinoma: relationship with lymph nodal involvement and 72 kDa-metalloproteinase index.
    Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Nictolis MD; Romanini C; Biagini G
    Anticancer Res; 1998; 18(1B):609-13. PubMed ID: 9568185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
    Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of ras oncogene p21 antigen in normal and proliferative thyroid tissues.
    Johnson TL; Lloyd RV; Thor A
    Am J Pathol; 1987 Apr; 127(1):60-5. PubMed ID: 3105323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential (Ha-, K- and N-) ras p21 expression in benign and malignant human thyroid tumors: an immunohistochemical study.
    Mizukami Y; Nonomura A; Michigishi T; Noguchi M; Nakamura S; Hashimoto T
    Anticancer Res; 1995; 15(3):755-9. PubMed ID: 7645954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of the ras oncogene protein product in human thyroid neoplasms.
    Papadimitriou K; Yiagnisis M; Tolis G; Spandidos DA
    Anticancer Res; 1988; 8(6):1223-7. PubMed ID: 3064713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunohistochemical studies of ras oncogene product p21 in human ovarian tumors].
    Yaginuma Y; Yamashita K
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1409-16. PubMed ID: 2685141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased expression of p107 is correlated with anaplastic transformation in papillary carcinoma of the thyroid.
    Ito Y; Yoshida H; Tomoda C; Uruno T; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Kuma K; Miyauchi A
    Anticancer Res; 2003; 23(5A):3819-24. PubMed ID: 14666683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Met expression in tall cell variant papillary carcinoma of the thyroid.
    Nardone HC; Ziober AF; LiVolsi VA; Mandel SJ; Baloch ZW; Weber RS; Mick R; Ziober BL
    Cancer; 2003 Oct; 98(7):1386-93. PubMed ID: 14508824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression and role of serum response factor in papillary carcinoma of the thyroid.
    Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
    Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma.
    Resnick MB; Schacter P; Finkelstein Y; Kellner Y; Cohen O
    Mod Pathol; 1998 Aug; 11(8):735-9. PubMed ID: 9720501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
    Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
    Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochemical assessments of the nuclear DNA distribution pattern by means of image and flow cytometry in thyroid neoplasms and in non-neoplastic thyroid lesions. A comparative methodological study.
    Wallin G; Askensten U; Bäckdahl M; Grimelius L; Lundell G; Auer G
    Acta Chir Scand; 1989; 155(4-5):251-8. PubMed ID: 2800873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical localization of acidic and basic fibroblast growth factors in human benign and malignant thyroid lesions.
    Kodama M; Daa T; Kashima K; Yokoyama S; Nakayama I; Noguchi S
    Jpn J Clin Oncol; 1994 Apr; 24(2):66-73. PubMed ID: 7512670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue.
    Fernández PL; Merino MJ; Gómez M; Campo E; Medina T; Castronovo V; Sanjuán X; Cardesa A; Liu FT; Sobel ME
    J Pathol; 1997 Jan; 181(1):80-6. PubMed ID: 9072007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoblastoma expression in thyroid neoplasms.
    Anwar F; Emond MJ; Schmidt RA; Hwang HC; Bronner MP
    Mod Pathol; 2000 May; 13(5):562-9. PubMed ID: 10824929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa.
    Visca P; Alò PL; Del Nonno F; Botti C; Trombetta G; Marandino F; Filippi S; Di Tondo U; Donnorso RP
    Clin Cancer Res; 1999 Dec; 5(12):4111-8. PubMed ID: 10632348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin expression is significantly linked to the dedifferentiation of thyroid carcinoma.
    Ito Y; Yoshida H; Uruno T; Nakano K; Miya A; Kobayashi K; Yokozawa T; Matsuzuka F; Matsuura N; Kakudo K; Kuma K; Miyauchi A
    Oncol Rep; 2003; 10(5):1337-40. PubMed ID: 12883703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma.
    Baek SK; Woo JS; Kwon SY; Lee SH; Chae YS; Jung KY
    Laryngoscope; 2007 May; 117(5):911-6. PubMed ID: 17473695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.